Adjunctive screening and risk stratification performance of neutrophil-to-lymphocyte ratio for gestational diabetes mellitus: A systematic review and meta-analysis.

Authors

Ling Chen, Wei Hu, Fei Zhao, Qian Pan, Chunhong Li, Xiangyuan Ju, Rennan Yao

Published in

Biomolecules & biomedicine. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

The neutrophil-to-lymphocyte ratio (NLR) is an inexpensive inflammatory marker with uncertain value for gestational diabetes mellitus (GDM) risk assessment. This systematic review and meta-analysis evaluated NLR for first-trimester risk stratification and second-trimester adjunctive screening of GDM. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to April 15, 2026. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Sensitivity and specificity were pooled separately by trimester, and summary receiver operating characteristic curves were fitted using the Moses-Littenberg method. Eleven studies comprising 12 independent datasets used the oral glucose tolerance test (OGTT) as the reference standard. Pooled sensitivity, specificity, and area under the curve (AUC), with 95% confidence intervals (CIs), were 0.702 (0.660-0.742), 0.426 (0.401-0.452), and 0.694 (0.559-0.828), respectively, in the first trimester and 0.665 (0.632-0.697), 0.644 (0.618-0.670), and 0.798 (0.723-0.873) in the second trimester. At cutoffs ≤ 3.0, exploratory AUC estimates were 0.845 and 0.850, respectively, but subgroup differences were not formally tested. All studies were at high risk of index-test bias from post hoc threshold selection, seven used case-control designs, and heterogeneity was substantial. NLR may have an adjunctive role in GDM risk assessment but should not replace OGTT or serve as a standalone screening test. No clinical cutoff can be recommended; prospective studies with prespecified thresholds and independent validation cohorts are required.

PMID:
42804757
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.